Arcellx (ACLX) News Today → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Free ACLX Stock Alerts $52.79 +1.07 (+2.07%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 2:42 AM | americanbankingnews.comArcellx (NASDAQ:ACLX) PT Raised to $83.00 at Stifel NicolausMay 16 at 6:38 AM | americanbankingnews.comArcellx (NASDAQ:ACLX) Upgraded to "Strong-Buy" at Evercore ISIMay 16 at 1:38 AM | americanbankingnews.comArcellx (NASDAQ:ACLX) Trading 6.6% Higher Following Analyst UpgradeMay 15 at 10:49 AM | marketbeat.comArcellx (NASDAQ:ACLX) Shares Up 6.6% Following Analyst UpgradeArcellx (NASDAQ:ACLX) Trading 6.6% Higher on Analyst UpgradeMay 15 at 9:01 AM | marketbeat.comArcellx (NASDAQ:ACLX) Price Target Increased to $83.00 by Analysts at Stifel NicolausStifel Nicolaus boosted their price objective on Arcellx from $82.00 to $83.00 and gave the stock a "buy" rating in a report on Wednesday.May 15 at 6:18 AM | americanbankingnews.comEvercore ISI Initiates Coverage on Arcellx (NASDAQ:ACLX)May 15 at 4:54 AM | americanbankingnews.comArcellx (NASDAQ:ACLX) PT Lowered to $80.00May 14 at 11:13 PM | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Arcellx Inc (ACLX)May 14 at 6:13 PM | msn.comEvercore ISI Group Initiates Coverage of Arcellx (ACLX) with Outperform RecommendationMay 14 at 9:43 AM | markets.businessinsider.comBuy Rating for Arcellx Inc. on Promising CAR-T Cell Therapy Trials and Strategic Market PositioningMay 14 at 9:43 AM | markets.businessinsider.comAnalyst Expectations For Arcellx's FutureMay 14 at 4:53 AM | marketbeat.comVictory Capital Management Inc. Raises Position in Arcellx, Inc. (NASDAQ:ACLX)Victory Capital Management Inc. boosted its stake in Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 425.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 155,652 shares of the company's stock after buyiMay 13, 2024 | marketbeat.comHC Wainwright Trims Arcellx (NASDAQ:ACLX) Target Price to $80.00HC Wainwright dropped their price target on shares of Arcellx from $82.00 to $80.00 and set a "buy" rating for the company in a research note on Monday.May 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arcellx Inc. Amidst Promising Trial Progress and Strategic PartnershipsMay 12, 2024 | finance.yahoo.comArcellx First Quarter 2024 Earnings: Beats ExpectationsMay 12, 2024 | americanbankingnews.comArcellx (NASDAQ:ACLX) Trading Down 6.1%May 11, 2024 | markets.businessinsider.comBuy Rating Justified for Arcellx Inc. Amidst Progress in Anito-cel’s Clinical Development and Regulatory MilestonesMay 10, 2024 | marketbeat.comArcellx (NASDAQ:ACLX) Stock Price Down 6.1%Arcellx (NASDAQ:ACLX) Trading Down 6.1%May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arcellx Inc on Robust iMMagine-3 Study Prospects and Efficient ManufacturingMay 10, 2024 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on Arcellx Inc (ACLX)May 10, 2024 | finance.yahoo.comArcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue SurgeMay 10, 2024 | marketbeat.comArcellx (NASDAQ:ACLX) Announces Quarterly Earnings ResultsArcellx (NASDAQ:ACLX - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.37. Arcellx had a negative return on equity of 20.96% and a negative net margin of 64.08%. The company had revenue of $39.26 million during the quarter, compared to analysts' expectations of $20.67 million. During the same period last year, the business earned ($0.58) earnings per share. The business's revenue was up 119.2% on a year-over-year basis.May 10, 2024 | markets.businessinsider.comBuy Rating for Arcellx Inc: Strategic Positioning and Promising Clinical Trials Fuel Positive OutlookMay 10, 2024 | investorplace.comACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | msn.comGilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma assetMay 9, 2024 | businesswire.comArcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramMay 9, 2024 | businesswire.comKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramMay 9, 2024 | businesswire.comArcellx Provides First Quarter 2024 Financial ResultsMay 9, 2024 | investorplace.comBiotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing MedicineMay 8, 2024 | americanbankingnews.comArcellx (NASDAQ:ACLX) Given "Buy" Rating at Needham & Company LLCMay 7, 2024 | markets.businessinsider.comBuy Rating and $81 Price Target for Arcellx Inc. Amidst Strong Market Potential and Strategic Gilead PartnershipMay 7, 2024 | businesswire.comArcellx to Participate in Two Upcoming Investor ConferencesMay 7, 2024 | marketbeat.comNeedham & Company LLC Reiterates "Buy" Rating for Arcellx (NASDAQ:ACLX)Needham & Company LLC reaffirmed a "buy" rating and set a $81.00 price objective on shares of Arcellx in a research report on Tuesday.May 4, 2024 | insidertrades.comArcellx, Inc. (NASDAQ:ACLX) Insider Christopher Heery Sells 18,168 SharesApril 26, 2024 | marketbeat.comStrs Ohio Sells 17,181 Shares of Arcellx, Inc. (NASDAQ:ACLX)Strs Ohio trimmed its position in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 58.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,300 shares of the company's stock after selling 17,181 sharesApril 24, 2024 | marketbeat.comFederated Hermes Inc. Acquires 143,212 Shares of Arcellx, Inc. (NASDAQ:ACLX)Federated Hermes Inc. grew its position in Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 200.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 214,599 shares of the company's stock after buying an additional 143,212 shares during thApril 23, 2024 | marketbeat.comArcellx (NASDAQ:ACLX) Stock Price Up 7.2%Arcellx (NASDAQ:ACLX) Stock Price Up 7.2%April 19, 2024 | marketbeat.comArcellx (NASDAQ:ACLX) Shares Down 3% Following Insider SellingArcellx (NASDAQ:ACLX) Stock Price Down 3% on Insider SellingApril 19, 2024 | insidertrades.comArcellx, Inc. (NASDAQ:ACLX) Director Olivia C. Ware Sells 9,402 SharesApril 18, 2024 | marketbeat.comInsider Selling: Arcellx, Inc. (NASDAQ:ACLX) Director Sells 9,402 Shares of StockArcellx, Inc. (NASDAQ:ACLX - Get Free Report) Director Olivia C. Ware sold 9,402 shares of Arcellx stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $55.55, for a total value of $522,281.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.April 12, 2024 | markets.businessinsider.comBuy Rating Backed by Potential Regulatory Tailwinds for Arcellx’s CAR-T TherapyApril 11, 2024 | msn.com3 Best Stocks to Buy Now, 4/11/2024, According to Top AnalystsApril 11, 2024 | marketbeat.comNeedham & Company LLC Reaffirms Buy Rating for Arcellx (NASDAQ:ACLX)Needham & Company LLC reissued a "buy" rating and issued a $81.00 price objective on shares of Arcellx in a research report on Thursday.April 7, 2024 | marketbeat.comArcellx, Inc. (NASDAQ:ACLX) Holdings Raised by Vanguard Group Inc.Vanguard Group Inc. boosted its holdings in Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 2.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,038,557 shares of the company's stock after aApril 4, 2024 | businesswire.comArcellx to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceApril 4, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX) and Adaptive Biotechnologies (ADPT)April 4, 2024 | marketbeat.comArcellx (NASDAQ:ACLX) Earns Outperform Rating from ScotiabankScotiabank restated an "outperform" rating and set a $82.00 price target on shares of Arcellx in a report on Thursday.April 4, 2024 | insidertrades.comArcellx, Inc. (NASDAQ:ACLX) Insider Rami Elghandour Sells 23,086 SharesApril 3, 2024 | marketbeat.comInsider Selling: Arcellx, Inc. (NASDAQ:ACLX) Insider Sells 23,086 Shares of StockArcellx, Inc. (NASDAQ:ACLX - Get Free Report) insider Rami Elghandour sold 23,086 shares of the business's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $67.09, for a total value of $1,548,839.74. Following the sale, the insider now directly owns 69,253 shares of the company's stock, valued at approximately $4,646,183.77. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.March 27, 2024 | finance.yahoo.comInsider Sell: Arcellx Inc's Chief Medical Officer Christopher Heery Disposes of 46,815 Shares Get Arcellx News Delivered to You Automatically Sign up to receive the latest news and ratings for ACLX and its competitors with MarketBeat's FREE daily newsletter. Email Address “Dollar Will Be Worth NOTHING” -Musk (Ad)Elon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher. Click here to claim your free seat ticket now. ACLX Media Mentions By Week ACLX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACLX News Sentiment▼0.560.54▲Average Medical News Sentiment ACLX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACLX Articles This Week▼273▲ACLX Articles Average Week Get Arcellx News Delivered to You Automatically Sign up to receive the latest news and ratings for ACLX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TWST News Today IMCR News Today DNLI News Today IOVA News Today VCEL News Today RXRX News Today SWTX News Today APGE News Today KYMR News Today ADMA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACLX) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDoes this make you sick?Allegiance GoldWhy Is Gold On a MASSIVE rally? Huge AlertsUrgent Alert: Is the U.S. Implementing a Digital Dollar?Gold Gate Capital348 million Americans lives to END as we know it?The Oxford ClubBiden Nomination CANCELED?The Freeport SocietyGold Set to EXPLODE!Gold Safe ExchangeDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcellx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
